Full Text View
Tabular View
No Study Results Posted
Related Studies
High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML)
This study has been completed.
Study NCT00707408   Information provided by Nantes University Hospital

First Received on June 26, 2008.   Last Updated on January 30, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
AML
Additional conditions recognized in this trial
Leukemia, Myeloid
Leukemia, Myeloid, Acute
More general conditions related to this trial
Leukemia
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Imatinib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Nantes University Hospital


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services